HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $17 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.5%

Neg 0% Neu 89.5% Pos 0%

HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $17 price target.